This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

  • identifier


  • Recruitment Status

    Active, not recruiting

  • First Posted

    February 11, 2021

  • Last update posted

    February 11, 2021

Study Description

Brief summary:

HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated.

  • Condition or Disease:Triple-negative Breast Cancer
  • Intervention/Treatment: Drug: HX008+Cisplatin+Gemcitabine
  • Phase: Phase 1/Phase 2

Detailed Description


Study Design

  • Study Type: Interventional
  • Actual Enrollment: 31 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Single-armed Multicenter Phase Ib / II Study of HX008 (a Recombinant Humanized Anti-PD-1 Monoclonal Antibody) Combined With GP Regimen as the First-line Treatment in Patients With Metastatic Triple Negative Breast Cancer
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: December 2020
  • Actual Study Completion Date: December 2021

Arms and interventions

Arm Intervention/treatment
Experimental: HX008+Cisplatin+Gemcitabine
Drug: HX008+Cisplatin+Gemcitabine
Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m^2, Day 1, Day 8, Q3W for up to 6 cycles

Outcome Measures

  • Primary Outcome Measures: 1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 24 months ]
  • 2. 1-year progression-free survival rate [ Time Frame: 24 months ]
    The rate of participants who neither experience disease progression nor death
  • Secondary Outcome Measures: 1. Objective Response Rate (ORR) [ Time Frame: 12 months ]
    Percentage of subjects achieving complete response (CR) and partial response (PR) according to RECIST1.1 and iRECIST.
  • 2. Duration of Response (DOR) [ Time Frame: 24 months ]
    Disease Control Rate (DCR) refers to the proportion of subjects who achieve CR, PR and SD through imaging evaluation.
  • 3. Overall survival (OS) [ Time Frame: 24 months ]
    Overall survival (OS) refers to the time from the first study drug treatment to death due to any cause.
  • 4. Progression-Free Survival (PFS) [ Time Frame: 24 months ]
    Progression-free survival (PFS) is defined as the time from the first study drug treatment to disease progression (PD) or to death of the subject due to any reason.

Eligibility Criteria

  • Ages Eligible for Study: 18 to 70 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Inclusion Criteria: Provide written informed consent voluntarily. Understand this protocol and be willing and able to adhere to the study visit schedule. Age 18-70 years old, male or female. Diagnosed with stage IV or recurrent or metastatic TNBC who are not suitable for surgical treatment. Histopathology shows that ER, PR and HER-2 are all negative. If metastasis exists, the histopathology result of metastasis is preferred. ER and PR negative are defined as ER < 1% and PR < 1%. HER-2 negative is defined as HER-2 (-) or (+) in immunohistochemical test. For HER-2 (++), additional negative result should be observed in FISH test. For HER-2 (-) or (+), FISH test is optional, but the result should be negative. Have not been treated with any chemotherapy drugs for recurrent and metastatic triple negative breast cancer (adjuvant / neoadjuvant therapy is allowed, if the time between the last dose of drug and recurrence or metastasis is more than 6 months). Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Score. Life expectancy ≥ 3 months. Has at least one measurable extracranial lesion according to RECIST1.1, which has not been treated with radiotherapy. Has sufficient organ and bone marrow function to meet the following laboratory examination standards: Blood routine: absolute neutrophil count (ANC)≥1.5×10^9/L; while blood cell count (WBC)≥3×10^9/L; platelet count (PLT)≥100×10^9/ L; hemoglobin (HGB)≥90 g/L (without blood transfusion within 14 days prior to enrollment); Renal function: serum creatinine (Scr) ≤1.5×ULN, and endogenous creatinine clearance is more than 50 ml / min (Cockcroft Gault formula); Liver function: TBIL≤1.5×ULN; Patients without liver metastases require alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN. Patients with liver metastases require: ALT and AST≤5×ULN; The coagulation function is adequate, which is defined as the international normalized ratio (INR) ≤ 2×ULN; or activated partial thromboplastin time (APTT)≤ 1.5×ULN (except for those who are receiving anticoagulant therapy if their PT/APTT are within the expected values); Reproductive men and women of childbearing age are willing to take effective contraceptive measures (such as oral contraceptives, intrauterine contraceptives, sexual abstinence or barrier contraceptives combined with spermicide) from signing the informed consent form to 12 months after the last administration of the trial drug. Exclusion Criteria: Suffered from other malignant tumors in the past 5 years, except carcinoma in situ from cervix or skin basal cell carcinoma that has been cured. With adverse reactions of previous treatment that have not be recovered to CTCAE V5.0 grade ≤ 1, except for the residual hair loss effect. Had prior treatment with any anti-PD-1, PD-L1 or CTLA-4 therapies. Participants with active or a history of autoimmune diseases that probably will recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulitis, etc.), or with high risk (e.g. organ transplantation requiring immunosuppressive therapy). However, participants with the following diseases are eligible: skin diseases requiring no systemic treatment (such as eczema, skin rash covering less than 10% of the body surface, psoriasis without ophthalmic symptoms, etc.). Expected to undergo major surgery during the study treatment or within 28 days before the first administration of the study drug (excluding surgery for diagnostic purpose). Need to receive systemic corticosteroids (dose equivalent to > 10 mg prednisone / day) or other immunosuppressive drugs within 14 days before enrollment or during the study period. Those under the following conditions are eligible: a) Locally external use or inhaled corticosteroids; b) short-term (≤ 7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases. Has active digestive ulcer, incomplete intestinal obstruction, active gastrointestinal hemorrhage or perforation. Has active interstitial pneumonia, pulmonary fibrosis, acute pulmonary disorders, acute radiation pneumonitis, et al. Has uncontrolled systemic diseases, such as cardiovascular and cerebrovascular diseases (unstable angina pectoris, etc.), diabetes, hypertension, tuberculosis, etc; Has a history of HIV infection, or other acquired or innate immune deficiency disorders, or a history of organ or stem-cell transplantation. Has active chronic HBV or HCV infection, except those with HBV DNA viral load ≤500 IU/mL or <10^3 copies/mL, or HCV RNA negative after adequate treatment. Has severe infection within 4 weeks or active infection requiring IV infusion or oral administration of antibiotics within 2 weeks prior to the first dose of the study drug. Known to be allergic to macromolecular protein agents or monoclonal antibody; Known to has a history of severe allergies (CTCAE v5.0 ≥ grade 3) to any of the components in the study drug. Has participated in other clinical trial within 4 weeks before the first administration of the study drug. Alcohol dependence or drug abuse within recent one year. Has a history of confirmed neurological or mental disorders, such as epilepsy, dementia; or with poor compliance; or the presence of peripheral neurological disorders. Has symptomatic central nervous system metastasis. Participants with asymptomatic central nervous system metastasis with or without treatment, who have no disease progression by CT / MRI examination, and whose interval from the last radiotherapy is more than 4 weeks, can be enrolled. Participants with uncontrollable pleural effusion, peritoneal effusion or pericardial effusion requiring repeated drainage within 7 days before enrollment. Participants who had received hematopoietic stimulating factors such as colony stimulating factor and erythropoietin within 2 weeks prior to the first dose of study drug Is pregnant or breastfeeding. Other reasons disqualifying the entering of this study based on the evaluation of the investigators.

Contacts and Locations



China, Shanghai
Fudan University Shanghai Cancer Center

Sponsors and Collaborators

Taizhou Hanzhong biomedical co. LTD


Study Chair: Xichun Hu Fudan University

More Information

  • Responsible Party: Taizhou Hanzhong biomedical co. LTD
  • Identifier: NCT04750382 History of Changes
  • Other Study ID Numbers: HX008-Ib/II-TNBC-01
  • First Posted: February 11, 2021 Key Record Dates
  • Last Update Posted: February 11, 2021
  • Last Verified: February 2021
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Breast Neoplasms
    Triple Negative Breast Neoplasms
    Neoplasms by Site
    Breast Diseases
    Skin Diseases